Study S001935

Phase 2 Study: A Double-blind, Randomised, Clinical Cross-over Trial to Investigate the Treatment Potential of Liraglutide Compared to Glimepiride in MODY Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01610934
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 15
Start: 2012-08
Primary completion: 2013-08
Lead sponsor: University Hospital, Gentofte, Copenhagen
Conditions: Maturity-onset Diabetes of the Young
Interventions: DRUG:liraglutide; DRUG:Glimepiride
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-000592-17

Registered primary outcomes

Fasting Plasma Glucose [14 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017904	Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Østoft SH, Diabetes care	2014	Randomized trial	PMID 24929431 DOI	cites ClinicalTrials.gov:NCT01610934; cites EudraCT:2012-000592-17; registry reference DERIVED:24929431